Global Discovery Biosciences (GD Biosciences), a company dedicated to developing, manufacturing and making innovative technology available to prevent and manage chronic disease, announced its partnership with LifeLabs Medical Laboratory Services (LifeLabs), Canada’s largest community laboratory provider, to make the PULS Cardiac Test available in Canada.
The PULS Cardiac Test is a simple blood test that identifies individuals who are at risk of experiencing a heart attack, and for whom early intervention can help. The PULS test measures the body’s immune response to arterial or endothelial injury that leads to formation and progression of cardiac lesions that can become unstable and rupture. Unstable cardiac lesion rupture is the most common cause of heart attack (causing up to 75% of all cardiac events) contrary to the commonly held mistaken belief that narrowing of the arteries causes most heart attacks. The PULS Cardiac Test provides physicians with this information so that with patients, they can take preventative action early on, when it is most effective to improve patient care and potentially prevent death or disability.
Heart Disease remains the leading cause of death and disability for both men and women in Canada and worldwide – despite being one of the most preventable diseases. It is often referred to as the “silent killer” because there are frequently no warning signs before a heart attack occurs.
“We are eager to reach the Canadian population with our PULS Cardiac Test and potentially prevent people from having Heart Attacks that could otherwise be avoided,” said Dr. Douglas Harrington, CEO and Medical Director of GD Biosciences, and creator of the PULS Cardiac Test.
“LifeLabs is an outstanding healthcare partner in Canada with a long history of quality and innovation, delivering optimum laboratory services to Canada.”
LifeLabs is a leading provider of laboratory testing services in Canada, performing over a 100 million tests each year. LifeLabs’ commitment to making innovations accessible to Canadians to improve disease prevention and management complements GD Biosciences in their mission with the PULS Cardiac Test to detect disease before it becomes a life-threatening event.
“We are very pleased to be working with GD Biosciences and making available the PULS test to all Canadians. We all appreciate the benefits of early diagnosis of disease, including heart disease and the PULS test is further evidence of LifeLabs commitment to bring new, innovative, clinically useful diagnostics to Canada in our effort to keep Canadians healthy” says Jeff Sumner, Senior Vice President, Business Development, Clinical Affairs and Genetics.
The announcement of the PULS Cardiac Test availability in Canada, follows GD Biosciences recent expansion of the PULS Cardiac Test into the United Kingdom and Germany, as well as a recent case study published online by the American College of Cardiology. For more information, or to request testing, visit www.pulstest.com
About GD Biosciences
Global Discovery Biosciences is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.
The company collaborates with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. As a CLIA-certified and GMP laboratory, our goal are to equip physicians with the tools they needed to transform health care – one patient at a time.
About LifeLabs: www.LifeLabs.com
LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help health care providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in health care. LifeLabs employs approximately 5,300 professionally trained staff and delivers over 100 million laboratory tests, supporting 19 million patient visits annually. In 2013, LifeLabs acquired BC Biomedical in British Columbia and CML HealthCare in Ontario making LifeLabs the largest community laboratory in Canada. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure
About the PULS Cardiac TestTM
The PULS Cardiac Test, developed by GD Biosciences, is a simple blood test that identifies individuals with active, yet undetected subclinical Coronary Heart Disease (CHD), who are at risk of experiencing a Heart Attack, and for whom early intervention can help. The test measures protein biomarkers of the body’s immune response to arterial injury leading to the formation and progression unstable cardiac lesions – the #1 cause of Heart Attacks. For more information, visit: www.pulstest.com.
Check out our recent news coverage:
Fox News Special Report – Technology Helps Predict Heart Attacks
Travel Pulse – Could Blood Test Warn Pilots of Heart Attack Risk?
Times Colonist – Blood test can assess Heart Attack risk, conference told
Saskatoon Star Phoenix – New test for Heart Attack risk
The Province – Blood test can assess Heart Attack risk, Vancouver conference hears
Lifescript – For Eric Roberts, an Oscars Gift Was a Lifesaver
MEDIA CONTACT:
For GDB:
Adam Farragut
PR Firm: The Publicity Agency
Email: Phone: 813-708-1220 x7778
Website: www.thepublicityagency.com
SOURCE: GD Biosciences
This press release is distributed by PR NewsChannel. Your News. Everywhere.
